Lee JH, et al. - In this single-center retrospective study, researchers compared rivaroxaban to dalteparin with respect to effectiveness and safety in treating cancer-associated venous thromboembolism (VTE) in patients with primary lung cancer. Overall 204 patients were included in this study. There were 131 treated with rivaroxaban and 73 received dalteparin for VTE. A composite event including recurrence and major or clinically relevant nonmajor bleeding was considered the primary endpoint. Findings revealed that the safety and effectiveness profile of rivaroxaban was not different vs dalteparin, so for the treatment of lung cancer-associated VTE, rivaroxaban may be a good option.